Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy

Strategies boosting both innate and adaptive immunity have great application prospects in cancer immunotherapy. Antibodies dual blocking the innate checkpoint CD47 and adaptive checkpoint PD-L1 or TIGIT could achieve durable anti-tumor effects. However, a small molecule dual blockade of CD47/SIRPα a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiuman, Jiao, Ling, Qian, Yuzhen, Dong, Qingyu, Sun, Yixuan, Zheng, Wei V., Zhao, Wenshan, Zhai, Wenjie, Qiu, Lu, Wu, Yahong, Wang, Hongfei, Gao, Yanfeng, Chen, Junhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150775/
https://www.ncbi.nlm.nih.gov/pubmed/34068552
http://dx.doi.org/10.3390/biom11050706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150775/
https://www.ncbi.nlm.nih.gov/pubmed/34068552
http://dx.doi.org/10.3390/biom11050706

Ejemplares similares